Does the presence of a KEAP1 mutation influence your decision to use adjuvant immunotherapy in stage II–III melanoma?

It is an interesting thought when you look at the mutations that may predict resistance towards checkpoint inhibitors. However, I do not think we are at a stage where we can make a firm decision in the adjuvant setting (or any other setting) based on mutation profile. If there is a concomitant BRAF ...